Ron Hj Mathijssen

49PUBLICATIONS

210CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)AllergyNanotoxicology, health and safetyMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (49)

Sort by Publication Date:

|Jun 24, 2026

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

|Jun 08, 2026

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A <i>DPYD</i> Variant Allele.

|May 25, 2026

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer.

|May 14, 2026

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.

|May 06, 2026

Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade.

|Apr 03, 2026

Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale.

Marzia Del Re, Elvira Inglese, Emilio Bria

Pageof 9

Frequent Collaborators

Esther Oomen-de Hoop

Henk-Jan Guchelaar

Ron H N van Schaik

Jesse J Swen

Anne-Marie C Dingemans

Stijn L W Koolen

Reno Debets

Alwin D R Huitema

Niels A D Guchelaar

Neeltje Steeghs

Frequent Collaborators

Esther Oomen-de Hoop

Henk-Jan Guchelaar

Ron H N van Schaik

Jesse J Swen